EMA Revises Acute Respiratory Distress Syndrome Expectations: Impact On Trial Patient Selection

 
• By Vibha Sharma

The European Medicines Agency is consulting on new requirements in its guideline on clinical trials for acute respiratory distress syndrome. The updates cover the selection of target population, choice of endpoints, use of biomarkers and pandemic preparedness.

Doctor with radiological chest x-ray film for medical diagnosis on patient’s health on COVID-19, asthma, lung disease and bone cancer illness, healthcare hospital service concept
Reduction of mortality is the most important treatment goal in ARDS patients (Shutterstock)

More from Europe

More from Pink Sheet